Table 1.
Clinicopathological characteristics of LIHC patients from the TCGA cohort.
| Characteristic | Low expression of BARX2 | High expression of BARX2 | p |
|---|---|---|---|
| n | 187 | 187 | |
| T stage, n (%) | |||
| T1 | 108 (29.1%) | 75 (20.2%) | 0.004 |
| T2 | 36 (9.7%) | 59 (15.9%) | |
| T3 | 34 (9.2%) | 46 (12.4%) | |
| T4 | 7 (1.9%) | 6 (1.6%) | |
| Pathologic stage, n (%) | |||
| Stage I | 103 (29.4%) | 70 (20%) | 0.020 |
| Stage II | 36 (10.3%) | 51 (14.6%) | |
| Stage III | 39 (11.1%) | 46 (13.1%) | |
| Stage IV | 2 (0.6%) | 3 (0.9%) | |
| Gender, n (%) | |||
| Female | 57 (15.2%) | 64 (17.1%) | 0.507 |
| Male | 130 (34.8%) | 123 (32.9%) | |
| Age, n (%) | |||
| < = 60 | 89 (23.9%) | 88 (23.6%) | 1.000 |
| > 60 | 98 (26.3%) | 98 (26.3%) | |
| OS event, n (%) | |||
| Alive | 118 (31.6%) | 126 (33.7%) | 0.447 |
| Dead | 69 (18.4%) | 61 (16.3%) | |
| Race, n (%) | |||
| Asian | 83 (22.9%) | 77 (21.3%) | 0.376 |
| Black or African American | 6 (1.7%) | 11 (3%) | |
| White | 88 (24.3%) | 97 (26.8%) | |
| Height, n (%) | |||
| < 170 | 108 (31.7%) | 93 (27.3%) | 0.408 |
| > = 170 | 68 (19.9%) | 72 (21.1%) | |
| Histologic grade, n (%) | |||
| G1 | 33 (8.9%) | 22 (6%) | 0.294 |
| G2 | 88 (23.8%) | 90 (24.4%) | |
| G3 | 56 (15.2%) | 68 (18.4%) | |
| G4 | 7 (1.9%) | 5 (1.4%) | |
| Residual tumor, n (%) | |||
| R0 | 172 (49.9%) | 155 (44.9%) | < 0.001 |
| R1 | 2 (0.6%) | 15 (4.3%) | |
| R2 | 1 (0.3%) | 0 (0%) | |
| Fibrosis ishak score, n (%) | |||
| 0 | 47 (21.9%) | 28 (13%) | 0.395 |
| 1/2 | 16 (7.4%) | 15 (7%) | |
| 3/4 | 15 (7%) | 13 (6%) | |
| 5/6 | 40 (18.6%) | 41 (19.1%) | |
| Vascular invasion, n (%) | |||
| No | 115 (36.2%) | 93 (29.2%) | 0.121 |
| Yes | 50 (15.7%) | 60 (18.9%) | |
| Age, median (IQR) | 62 (52, 69.5) | 61 (51.25, 68) | 0.539 |
n number of patients, IQR interquartile range.